Vertex Pharmaceuticals, Inc.

Other

Merck Patent Gmbh

Merck Canada Inc.

Merck Sharp + Dohme Corp.

Michael John Boyd

Tiansheng Wang

Hongbo Deng

Michael P Clark

Francois Maltais

Mark Willem Ledeboer

Upul Keerthi Bandarage

Brian Ledford

Wenxin Gu

David J Lauffer

Guy W Bemis

Pan Li

Luc J Farmer

Qing Tang

Nathan D Waal

Warren A Dorsch

Steven M Ronkin

Paul S Charifson

Emanuele Perola

Huai Gao

Randy Scott Bethiel

John P Duffy

Joseph M Kennedy

Ioana Davies

Michael Aaron Brodney

John Patrick Maxwell

Kevin Michael Cottrell

Dennis James Hurley

David D Deininger

Jinwang Xu

Simon Giroux

Adam R Looker

Ales Medek

Yi Shi

Ronald Lee Grey, Jr

Stefanie Roeper

Stephen Andrew Thomson

Lev Tyler Dewey Fanning

Henry Yu

Michael Waldo

Kathy Stavropoulos

Jeremy Green

Joey Lee Methot

Alex Aronov

John Colucci

Hardwin O'Dowd

Yuegang Zhang

Philip N Collier

Vouy Linh Truong

Mac Arthur Johnson, Jr

Marina S Penney

Russell R Hoover

Darin Takemoto

Kevin Gagnon

Peter D Jones

Philippe Marcel Nuhant

Brad D Maxwell

Diane M Boucher

Huijun Dong

Cavan McKeon Bligh

Setu Roday

Sarathy Kesavan

Amy Beth Hall

Robert Francis Fimognari, Jr

Kishan Chandupatla

Veronique Damagnez

Rupa Sawant

Rebecca Jane Swett

Timothy Lewis Tapley

Sarah Carol Hood

Pedro Manuel Garcia Barrantes

Muna Shrestha

Philip Collier

Kirk Overhoff

Mariam Zaky

Shashank Kukarni

Mei-Hsiu Lai

Marisa Sposato

Siying Liu

Gabrielle Simone Fleming

Robert Daniel Giacometti

Samantha Guido

Carl Berthelette

Carmela Molinaro

Sheldon N Crane

Dean Shannon

Kwame Wiredu Nti-Addae

Vouy-Linh Truong

Shashank Kulkarni

Mettachit Navamal

Karine M Villeneuve

André Giroux

David B Miller, Jr

Joshua Kennedy Hussey

Mary Elizabeth Eccles

Valerie Ann Cwynar

Jean-Francois Chiasson

Amelie Roy

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Pteridinone compounds and uses thereof

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Modulators of alpha-1 antitrypsin

The present invention provides compounds of Formula I', or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Antiproliferation compounds and uses thereof

Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).

A device and method of producing electrical energy by gravitomagnetic induction utilizing Nano-features fabricated on an object surface of an object is presented. The Nano-features may include Nano-bumps and Nano-pits. One device version includes a computer hard disk, a piezoelectric glide head, and/or a GMR read head, a prior art hard drive module electronics. By spinning the nano-features disk one produces an associated magnetic force utilizing a GMR read head for producing power by the presence or the absence of matter on an object that is in motion relative to the GMR read head. A computer system generated by the alternate computer system generates gravito-magnetic energy to power itself and/or other electrical or electronic devices, and/or, detects patterns of asperities or bump on a hard disk to generate binary value private keys applicable in asymmetric cryptography, such as public key cryptography.

Device and method to generate and apply gravito-magnetic energy

A wrist band system includes a body having a first strap integral with a second strap, the first strap and the second strap joining at a top face and having a side face; an opening extending through the thickness of the top face a housing extending from an outer surface of the first strap, the housing having a port; a plurality of lights secured to the side face; and a power source disposed within the body and conductively coupled to both the port and the plurality of lights.

Wrist light system and method of use

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

A method of preparing a compound of Formula (I) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (1): or a pharmaceutically acceptable salt thereof with Compound (2): in the presence of water, an organic solvent, a base, and a transition metal catalyst to generate a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Methods of preparing inhibitors of influenza viruses replication

The present invention relates to a compound useful as a selective inhibitor of PI3K&#x3b3;. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Selective inhibitor of phosphatidylinositol 3-kinase-gamma

Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

Growing community of inventors

Winchester, MA, United States of America

Michael John Boyd